細胞治療と遺伝子治療製造サービス市場

出版：MarketsandMarkets

Cell & Gene Therapy Manufacturing Services Market by Type (Allogeneic, Autologous, Viral Vector, Non-viral vector), Indication (Cancer, Orthopedic), Application (Clinical, Commercial), End User (Pharma & Biotech, Academia) – Global Forecast to 2026

–

–

細胞治療と遺伝子治療製造サービス市場のタイプ（同種異系、自家、ウイルスベクター、非ウイルスベクター）、適応症（癌、整形外科）、用途（臨床、商業）、エンドユーザー（製薬およびバイオテクノロジー、アカデミア）

The global cell & gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7billion in 2021, at a CAGR of 12.4% during the forecast period. Growth in this market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs. However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of this market to a certain extent.
“The clinical manufacturing segment accounted for the highest growth rate in thecell & gene therapy manufacturing servicesmarket, byapplication, during the forecast period”
The cell & gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing on the basis of application. The clinical manufacturing segment accounted for the highest growth rate in the cell & gene therapy manufacturing servicesmarket during the forecast period. This segment’s high growth rate can be attributed to increasing government funding for cancer research and the increasing number of cell & gene therapy clinical trials.
“Pharmaceutical & biotechnology companies segment accounted for the highest CAGR”
Based on end users, the cell & gene therapy manufacturing servicesmarket is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. During the forecast periodpharmaceutical & biotechnology companies accounted for the highest growth rate. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.
“Cell Therapy segment accounted for the highest CAGR”
Based on type, the cell & gene therapy manufacturing servicesmarket is segmented intocell therapy and gene therapy. The cell therapy segment accounted for the highest growth rate during the forecast period. Growth in this market is mainly driven by the increasing awareness about cell therapy, growing funding for new cell lines, increasing partnerships and acquisitions, and the development of advanced genomics methods for cell analysis.

“Infectious diseases segment accounted for the highest CAGR”
Based on indication, the cell & gene therapy manufacturing servicesmarket is segmented into oncology diseases, cardiovascular diseases, orthopedic diseases, ophthalmology diseases, infectious diseases, central nervous system disorders, and other indications. Theinfectious diseases segment accounted for the highest growth rate during the forecast period. The growth of this segment is attributed to the rising clinical trials for the development of cell therapies owing to the increasing prevalence of infectious diseases.
“Asia Pacific: The fastest-growing countryin thecell & gene therapy manufacturing servicesmarket”
TheCell & gene therapy manufacturing servicesmarket is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Increasing pharmaceutical R&D spending, the growing trend of outsourcing drug discovery services, growing life sciences research, and increasing government initiatives for healthcare research are the factors driving the growth of the cell & gene therapy manufacturing servicesmarket in this region.

The primary interviews conducted for this report can be categorized as follows:

•By Respondent: Supply Side- 70%, and Demand Side -30%
•By Designation (Supply Side): Managers – 45%, CXOs and Directors – 30%, and Executives- 25%
•By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of Companies Profiled in the Report:
•Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
•Charles River Laboratories (US)
• Lonza (Switzerland)
•Catalent, Inc. (US)
•WuXiAppTec (China)
•Takara Bio Inc. (Japan)
•NIKON CORPORATION (Japan)
•FUJIFILM Holdings Corporation (Japan)
•F. Hoffmann-La Roche Ltd. (Switzerland)
•Oxford Biomedica plc (UK)
•Cell and Gene Therapy Catapult (UK)
•The Discovery Labs LLC (US)
•RoslinCT (Scotland)
•JRS PHARMA (Germany)
•FinVector (Finland)
•ABL, Inc. (US)
•Resilience (US)
•BioCentriq (US)
•Porton Biopharma Limited (England)
•Andelyn Biosciences (US)
•Commercializing Living Therapies (Canada)
•Vibalogics (US)
•AnemocyteSrl (Italy)
•ElevateBio (US)
Research Coverage:
This report provides a detailed picture of the cell & gene therapy manufacturing servicesmarket. It aims at estimating the size and future growth potential of the market across different segments, such as type, indication, application, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell & gene therapy manufacturing servicesmarket and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

目次

1INTRODUCTION45
1.1OBJECTIVES OF THE STUDY45
1.2MARKET DEFINITION45
1.2.1INCLUSIONS & EXCLUSIONS45
1.3MARKET SCOPE46
1.3.1MARKETS COVERED46
1.3.2YEARS CONSIDERED IN THE REPORT47
1.4CURRENCY47
1.5LIMITATIONS47
1.6STAKEHOLDERS48
2RESEARCH METHODOLOGY49
2.1RESEARCH DATA49
FIGURE 1RESEARCH DESIGN49
2.1.1SECONDARY DATA50
2.1.2PRIMARY DATA50
FIGURE 2PRIMARY SOURCES51
FIGURE 3CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
BREAKDOWN OF PRIMARIES51
2.1.2.1Key industry insights52
2.2MARKET SIZE ESTIMATION53
FIGURE 4MARKET SIZE ESTIMATION: APPROACH 1 –
REVENUE SHARE ANALYSIS, 202053
FIGURE 5AVERAGE MARKET SIZE ESTIMATION, 202054
FIGURE 6CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
CAGR PROJECTIONS, 2021–202655
FIGURE 7CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES56
2.3MARKET BREAKDOWN AND DATA TRIANGULATION57
FIGURE 8DATA TRIANGULATION METHODOLOGY57
2.4RESEARCH ASSUMPTIONS58
2.5RISK ANALYSIS58
3EXECUTIVE SUMMARY59
FIGURE 9CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION)59
FIGURE 10CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2021 VS. 2026 (USD MILLION)60
FIGURE 11CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2021 VS. 2026 (USD MILLION)60
FIGURE 12CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)61
FIGURE 13GEOGRAPHICAL SNAPSHOT OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET62
4PREMIUM INSIGHTS63
4.1CELL & GENE THERAPY MANUFACTURING SERVICES MARKET OVERVIEW63
FIGURE 14HIGH INCIDENCE OF CANCER AND OTHER TARGET DISEASES TO
DRIVE MARKET GROWTH63
4.2NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE & COUNTRY (2020)64
FIGURE 15THE CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF
THE NORTH AMERICAN MARKET IN 202064
4.3CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE,
BY APPLICATION, 202064
FIGURE 16THE CLINICAL MANUFACTURING SEGMENT DOMINATED THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET IN 202064
4.4CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2021–202665
FIGURE 17ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD65
5MARKET OVERVIEW66
5.1INTRODUCTION66
5.2MARKET DYNAMICS66
FIGURE 18CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES66
TABLE 1CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
IMPACT ANALYSIS67
5.2.1DRIVERS67
5.2.1.1High incidence of cancer and other target diseases67
5.2.1.2Increasing investments in pharmaceutical R&D68
FIGURE 19INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–201668
5.2.1.3Investments in advanced technologies by CDMOs69
5.2.1.4Increasing partnerships and agreements between pharmaceutical companies and CDMOs69
5.2.2RESTRAINTS70
5.2.2.1High operational costs associated with cell & gene therapy manufacturing70
5.2.3OPPORTUNITIES70
5.2.3.1Rising demand for cell & gene therapies70
5.2.3.2Increasing number of cell & gene therapy clinical trials71
5.2.4CHALLENGES71
5.2.4.1Risk of mutagenesis and other unwanted outcomes71
5.2.5TRENDS71
5.2.5.1Expansion in emerging countries71
5.3IMPACT OF THE COVID-19 OUTBREAK ON THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET72
FIGURE 20CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SCENARIO, PRE-COVID-19 VS. POST-COVID-19 IMPACT, 2019–202173
5.4TECHNOLOGICAL ANALYSIS73
5.5CASE STUDIES74
5.5.1CGT CATAPULT PROVIDED ITS EXPERTISE IN THERAPIES DEVELOPMENT
AND MANUFACTURING TO CREATE A NEW PRECLINICAL DEVELOPMENT PLAN FOR PURESPRING THERAPEUTICS’ GENE THERAPY TECHNOLOGY FOR
KIDNEY DISEASES74
5.6RANGES/SCENARIO74
FIGURE 21SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES
ON THE GROWTH OF THE CELL & GENE THERAPY MANUFACTURING
SERVICES MARKET74
5.7TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES75
FIGURE 22REVENUE SHIFT & NEW POCKETS FOR CELL & GENE THERAPY MANUFACTURING SERVICE PROVIDERS75
5.8PRICING ANALYSIS75
5.9VALUE CHAIN ANALYSIS75
FIGURE 23VALUE CHAIN ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: HARVESTING AND CRYOPRESERVATION PHASES ADD MAXIMUM VALUE76
5.10ECOSYSTEM ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET76
FIGURE 24ECOSYSTEM ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET76
TABLE 2SUPPLY CHAIN ECOSYSTEM77
5.11PORTER’S FIVE FORCES ANALYSIS78
TABLE 3CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
PORTER’S FIVE FORCES ANALYSIS78
5.11.1THREAT FROM NEW ENTRANTS78
5.11.2THREAT FROM SUBSTITUTES78
5.11.3BARGAINING POWER OF BUYERS78
5.11.4BARGAINING POWER OF SUPPLIERS78
5.11.5INTENSITY OF COMPETITIVE RIVALRY79
5.12REGULATORY ANALYSIS79
5.12.1NORTH AMERICA79
5.12.1.1US79
5.12.1.2Canada79
5.12.2EUROPE79
5.12.2.1Germany79
5.12.2.2France79
5.12.2.3UK80
5.12.2.4Rest of Europe80
5.12.3ASIA PACIFIC80
5.12.3.1China80
5.12.3.2Japan80
5.12.3.3Rest of Asia Pacific81
5.12.3.3.1India81
5.12.3.3.2Australia and New Zealand81
5.12.4LATIN AMERICA81
5.12.5MIDDLE EAST & AFRICA82
5.13PATENT ANALYSIS82
FIGURE 25NUMBER OF PATENT APPLICATIONS FILED FOR CELL & GENE THERAPY MANUFACTURING SERVICES, JANUARY 2010–DECEMBER 202082
6CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE83
6.1INTRODUCTION84
TABLE 4CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)84
6.2CELL THERAPY84
TABLE 5CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)84
TABLE 6CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION)85
TABLE 7NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)85
TABLE 8EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)85
TABLE 9ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)86
6.2.1ALLOGENEIC86
TABLE 10ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)86
TABLE 11ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION)87
TABLE 12NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)87
TABLE 13EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)87
TABLE 14ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)88
6.2.1.1Mesenchymal stem cells88
6.2.1.1.1MSCs are ideal for cell therapy because of their immunosuppressive and tissue repair properties88
TABLE 15ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)88
TABLE 16NORTH AMERICA: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)89
TABLE 17EUROPE: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)89
TABLE 18ASIA PACIFIC: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)89
6.2.1.2T-cells90
6.2.1.2.1Allogeneic T-Cells are immediately available because of cryopreserved batches90
TABLE 19ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)90
TABLE 20NORTH AMERICA: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)90
TABLE 21EUROPE: ALLOGENEIC T-CELLS MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)91
TABLE 22ASIA PACIFIC: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)91
6.2.1.3Induced pluripotent stem cells91
6.2.1.3.1Growing adoption Of IPSCs in research to
drive market growth91
TABLE 23ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)92
TABLE 24NORTH AMERICA: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)92
TABLE 25EUROPE: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)92
TABLE 26ASIA PACIFIC: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)93
6.2.1.4Natural killer cells93
6.2.1.4.1Allogeneic natural killer cell therapies are used for advanced hepatocellular carcinoma patients93
TABLE 27ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)93
TABLE 28NORTH AMERICA: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)94
TABLE 29EUROPE: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)94
TABLE 30ASIA PACIFIC: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)94
6.2.1.5Hematopoietic stem cells95
6.2.1.5.1Stem cells from a donor are used for allogeneic transplantation95
TABLE 31ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)95
TABLE 32NORTH AMERICA: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)95
TABLE 33EUROPE: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)96
TABLE 34ASIA PACIFIC: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)96
 
6.2.1.6Other allogeneic cells96
TABLE 35OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)97
TABLE 36NORTH AMERICA: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)97
TABLE 37EUROPE: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)97
TABLE 38ASIA PACIFIC: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)98
6.2.2AUTOLOGOUS98
TABLE 39AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)98
TABLE 40AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION)99
TABLE 41NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)99
TABLE 42EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)99
TABLE 43ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)100
6.2.2.1T-cells100
6.2.2.1.1T-cells are major components of the adaptive
immune system100
TABLE 44AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)101
TABLE 45NORTH AMERICA: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)101
TABLE 46EUROPE: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)101
TABLE 47ASIA PACIFIC: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)102
6.2.2.2Hematopoietic stem cells102
6.2.2.2.1Hematopoietic stem cells are used to establish marrow
and bone function102
TABLE 48AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)102
TABLE 49NORTH AMERICA: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)103
TABLE 50EUROPE: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)103
TABLE 51ASIA PACIFIC: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)103
6.2.2.3Mesenchymal stem cells104
6.2.2.3.1Mesenchymal stem cells are present in the umbilical
cord, bone marrow, & fat tissue104
TABLE 52AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)104
TABLE 53NORTH AMERICA: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)104
TABLE 54EUROPE: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)105
TABLE 55ASIA PACIFIC: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)105
6.2.2.4Natural killer cells105
6.2.2.4.1NK Cells are used in the treatment of tumors and
infectious diseases105
TABLE 56AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)106
TABLE 57NORTH AMERICA: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)106
TABLE 58EUROPE: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)106
TABLE 59ASIA PACIFIC: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)107
6.2.2.5Other autologous cells107
TABLE 60OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION)107
TABLE 61NORTH AMERICA: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)108
TABLE 62EUROPE: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)108
TABLE 63ASIA PACIFIC: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)108
6.2.3VIRAL VECTOR109
TABLE 64VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)109
TABLE 65VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION)109
TABLE 66NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)110
TABLE 67EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)110
TABLE 68ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)110
6.2.3.1Retroviral vectors111
6.2.3.1.1Retroviral vectors are the most used viral vectors for cell therapy manufacturing111
TABLE 69RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)111
TABLE 70NORTH AMERICA: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)111
TABLE 71EUROPE: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)112
TABLE 72ASIA PACIFIC: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)112
6.2.3.2Adeno-associated virus vectors112
6.2.3.2.1AAV vector-based techniques are used for car-t cell
therapy development112
TABLE 73ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)113
TABLE 74NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)113
TABLE 75EUROPE: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)113
TABLE 76ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)114
6.2.3.3Other viral vectors114
TABLE 77OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)114
TABLE 78NORTH AMERICA: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)115
TABLE 79EUROPE: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)115
TABLE 80ASIA PACIFIC: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)115
6.3GENE THERAPY116
TABLE 81GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR,
2019–2026 (USD MILLION)116
TABLE 82GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION)116
TABLE 83NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)117
TABLE 84EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)117
TABLE 85ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)117
6.3.1NON-VIRAL VECTORS118
TABLE 86NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)118
TABLE 87NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION)118
TABLE 88NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)119
TABLE 89EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)119
TABLE 90ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)119
6.3.1.1Oligonucleotides120
6.3.1.1.1North America accounted for the largest share of the oligonucleotides market120
TABLE 91OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)120
TABLE 92NORTH AMERICA: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)120
TABLE 93EUROPE: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)121
TABLE 94ASIA PACIFIC: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)121
6.3.1.2Other non-viral vectors121
TABLE 95OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION)122
TABLE 96NORTH AMERICA: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)122
TABLE 97EUROPE: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)122
TABLE 98ASIA PACIFIC: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)123
6.3.2VIRAL VECTORS123
TABLE 99VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)123
TABLE 100VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION)124
TABLE 101NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)124
TABLE 102EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)124
TABLE 103ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)125
6.3.2.1Retroviral vectors125
6.3.2.1.1Retroviral vectors possess the ability to replicate
within a cell125
TABLE 104RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)126
TABLE 105NORTH AMERICA: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)126
TABLE 106EUROPE: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)126
TABLE 107ASIA PACIFIC: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)127
6.3.2.2Adeno-associated virus vectors127
6.3.2.2.1Adeno-associated virus vectors have low toxicity127
TABLE 108ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)128
TABLE 109NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)128
TABLE 110EUROPE: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)128
TABLE 111ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)129
6.3.2.3Other viral vectors129
TABLE 112OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)129
TABLE 113NORTH AMERICA: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)130
TABLE 114EUROPE: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)130
TABLE 115ASIA PACIFIC: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)130
7CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION131
7.1INTRODUCTION132
TABLE 116CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)132
7.2ONCOLOGY DISEASES132
7.2.1THE DEMAND FOR CELL & GENE THERAPIES IS INCREASING WITH THE RISING NUMBER OF CANCER CASES WORLDWIDE132
TABLE 117CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY REGION, 2019–2026 (USD MILLION)133
TABLE 118NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY,
2019–2026 (USD MILLION)133
TABLE 119EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)134
TABLE 120ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)134
7.3CARDIOVASCULAR DISEASES134
7.3.1GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES DRIVES THE MARKET GROWTH134
TABLE 121CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2026 (USD MILLION)135
TABLE 122NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY,
2019–2026 (USD MILLION)135
TABLE 123EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)135
TABLE 124ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY,
2019–2026 (USD MILLION)136
7.4ORTHOPEDIC DISEASES136
7.4.1CELL THERAPY FOR ORTHOPEDIC DISEASES ELIMINATES
POST-TREATMENT COMPLICATIONS136
TABLE 125CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY REGION, 2019–2026 (USD MILLION)136
TABLE 126NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY,
2019–2026 (USD MILLION)137
TABLE 127EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)137
TABLE 128ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)137
7.5OPTHALMOLOGY DISEASES138
7.5.1STEM CELL THERAPIES CAN BE USED FOR THE RESTORATION & PRESERVATION OF VISION; KEY FACTOR DRIVING MARKET GROWTH138
TABLE 129CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY REGION, 2019–2026 (USD MILLION)138
TABLE 130NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY,
2019–2026 (USD MILLION)138
TABLE 131EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)139
TABLE 132ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)139
7.6CENTRAL NERVOUS SYSTEM DISORDERS139
7.6.1INCREASING INCIDENCE OF SPINAL MUSCULAR ATROPHY SUPPORTS
THE MARKET GROWTH139
TABLE 133CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2019–2026 (USD MILLION)140
TABLE 134NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY,
2019–2026 (USD MILLION)140
TABLE 135EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY,
2019–2026 (USD MILLION)140
TABLE 136ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY,
2019–2026 (USD MILLION)141
7.7INFECTIOUS DISEASES141
7.7.1THE INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE
THE MARKET GROWTH OF THIS SEGMENT141
TABLE 137CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)142
TABLE 138NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2019–2026 (USD MILLION)142
TABLE 139EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)142
TABLE 140ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)143
7.8OTHER INDICATIONS143
TABLE 141CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY REGION, 2019–2026 (USD MILLION)143
TABLE 142NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)144
TABLE 143EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)144
TABLE 144ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)144
8CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION145
8.1INTRODUCTION146
TABLE 145CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)146
8.2CLINICAL MANUFACTURING146
8.2.1THE RISING NUMBER OF CLINICAL TRIALS FOR CELL & GENE THERAPIES IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT146
TABLE 146CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY REGION, 2019–2026 (USD MILLION)147
TABLE 147NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY,
2019–2026 (USD MILLION)147
TABLE 148EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)147
TABLE 149ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)148
8.3COMMERCIAL MANUFACTURING148
8.3.1MARKET GROWTH CAN BE ATTRIBUTED TO THE INCREASING APPROVALS OF CELL & GENE THERAPY PRODUCTS FOR COMMERCIAL MANUFACTURING148
TABLE 150CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY REGION, 2019–2026 (USD MILLION)148
TABLE 151NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY,
2019–2026 (USD MILLION)149
TABLE 152EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)149
TABLE 153ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY,
2019–2026 (USD MILLION)149
9CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER150
9.1INTRODUCTION151
TABLE 154CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)151
9.2PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES151
9.2.1GROWING NUMBER OF CELL & GENE THERAPIES IN THE R&D PIPELINE TO DRIVE THE MARKET GROWTH151
TABLE 155CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,
2019–2026 (USD MILLION)152
TABLE 156NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES,
BY COUNTRY, 2019–2026 (USD MILLION)152
TABLE 157EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2019–2026 (USD MILLION)153
TABLE 158ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)153
9.3ACADEMIC & RESEARCH INSTITUTES153
9.3.1INCREASE IN LIFE SCIENCES R&D EXPENDITURE TO CONTRIBUTE TO THE GROWTH OF THIS SEGMENT153
TABLE 159CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)154
TABLE 160NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,
2019–2026 (USD MILLION)154
TABLE 161EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,
2019–2026 (USD MILLION)155
TABLE 162ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY,
2019–2026 (USD MILLION)155
9.4OTHER END USERS155
TABLE 163CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)156
TABLE 164NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)156
TABLE 165EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)156
TABLE 166ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)157
10CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION158
10.1INTRODUCTION159
TABLE 167CELL & GENE THERAPY MANUFACTURING THERAPY SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION)159
10.2NORTH AMERICA159
FIGURE 26NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SNAPSHOT160
TABLE 168NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)160
TABLE 169NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)161
TABLE 170NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)161
TABLE 171NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)161
TABLE 172NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)162
TABLE 173NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)162
TABLE 174NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET,
BY VECTOR, 2019–2026 (USD MILLION)162
TABLE 175NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)163
TABLE 176NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)163
TABLE 177NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)163
TABLE 178NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)164
TABLE 179NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)164
10.2.1US164
10.2.1.1Growing focus on cancer research in the US will drive market growth164
TABLE 180US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)165
TABLE 181US: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)165
TABLE 182US: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)165
TABLE 183US: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)166
TABLE 184US: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)166
TABLE 185US: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)166
TABLE 186US: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)167
TABLE 187US: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)167
TABLE 188US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)167
TABLE 189US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)168
TABLE 190US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)168

10.2.2CANADA168
10.2.2.1Growth in Canada can be attributed to the rising funding for stem cell research in the country168
TABLE 191CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)169
TABLE 192CANADA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)169
TABLE 193CANADA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)170
TABLE 194CANADA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)170
TABLE 195CANADA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)170
TABLE 196CANADA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)171
TABLE 197CANADA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)171
TABLE 198CANADA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)171
TABLE 199CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)172
TABLE 200CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)172
TABLE 201CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)172
10.3EUROPE173
TABLE 202EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY COUNTRY, 2019–2026 (USD MILLION)173
TABLE 203EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)173
TABLE 204EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)173
TABLE 205EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)174
TABLE 206EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)174
TABLE 207EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)174
TABLE 208EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)175
TABLE 209EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)175
TABLE 210EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)175
TABLE 211EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)176
TABLE 212EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)176
TABLE 213EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)176
10.3.1GERMANY177
10.3.1.1Government funding for life science R&D and basic cancer research will drive market growth177
TABLE 214GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)177
TABLE 215GERMANY: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)177
TABLE 216GERMANY: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)178
TABLE 217GERMANY: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)178
TABLE 218GERMANY: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)178
TABLE 219GERMANY: GENE THERAPY MANUFACTURING SERVICES MARKET,
BY VECTOR, 2019–2026 (USD MILLION)179
TABLE 220GERMANY: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)179
TABLE 221GERMANY: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)179
TABLE 222GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)180
TABLE 223GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)180
TABLE 224GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)180
10.3.2UK181
10.3.2.1The rising incidence of cancer cases will lead to an increase in cancer research, which will drive market growth181
TABLE 225UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)181
TABLE 226UK: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)181
TABLE 227UK: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)182
TABLE 228UK: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)182
TABLE 229UK: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)182
TABLE 230UK: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)183
TABLE 231UK: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)183
TABLE 232UK: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)183
TABLE 233UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)184
TABLE 234UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)184
TABLE 235UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)184
10.3.3FRANCE185
10.3.3.1Growth can be attributed to rising government funding for
cancer research185
TABLE 236FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)185
TABLE 237FRANCE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)185
TABLE 238FRANCE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)186
TABLE 239FRANCE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)186
TABLE 240FRANCE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)186
TABLE 241FRANCE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)187
TABLE 242FRANCE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)187
TABLE 243FRANCE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)187
TABLE 244FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)188
TABLE 245FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)188
TABLE 246FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)188
10.3.4REST OF EUROPE189
TABLE 247ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)189
TABLE 248ROE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)189
TABLE 249ROE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)190
TABLE 250ROE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)190
TABLE 251ROE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)190
TABLE 252ROE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)191
TABLE 253ROE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)191
TABLE 254ROE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)191
TABLE 255ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)192
TABLE 256ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)192
TABLE 257ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)192
10.4ASIA PACIFIC193
FIGURE 27ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING
SERVICES MARKET SNAPSHOT193
TABLE 258ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)194
TABLE 259ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)194
TABLE 260ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)194
TABLE 261ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)195
TABLE 262ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)195
TABLE 263ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)195
TABLE 264ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET,
BY VECTOR, 2019–2026 (USD MILLION)196
TABLE 265ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)196
TABLE 266ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)196
TABLE 267ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)197
TABLE 268ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)197
TABLE 269ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)197
10.4.1CHINA198
10.4.1.1The growing pharmaceutical industry and rising number of CDMOs in the country will drive market growth198
TABLE 270CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)198
TABLE 271CHINA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)199
TABLE 272CHINA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)199
TABLE 273CHINA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)199
TABLE 274CHINA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)200
TABLE 275CHINA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)200
TABLE 276CHINA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)200
TABLE 277CHINA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)201
TABLE 278CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)201
TABLE 279CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)201
TABLE 280CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)202
10.4.2JAPAN202
10.4.2.1Research collaborations and growing geriatric population—
key growth drivers in Japan202
TABLE 281JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)203
TABLE 282JAPAN: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)203
TABLE 283JAPAN: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)203
TABLE 284JAPAN: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)204
TABLE 285JAPAN: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)204
TABLE 286JAPAN: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)204
TABLE 287JAPAN: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)205
TABLE 288JAPAN: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)205
TABLE 289JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)205
TABLE 290JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)206
TABLE 291JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)206
10.4.3REST OF ASIA PACIFIC206
TABLE 292ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)207
TABLE 293ROAPAC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)207
TABLE 294ROAPAC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)208
TABLE 295ROAPAC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)208
TABLE 296ROAPAC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)208
TABLE 297ROAPAC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)209
TABLE 298ROAPAC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)209
TABLE 299ROAPAC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)209
TABLE 300ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)210
TABLE 301ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)210
TABLE 302ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)210
10.5LATIN AMERICA211
10.5.1RISING PHARMACEUTICAL R&D EXPENDITURE IN THE REGION WILL DRIVE THE GROWTH OF THE MARKET211
TABLE 303LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)211
TABLE 304LATAM: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)211
TABLE 305LATAM: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)212
TABLE 306LATAM: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)212
TABLE 307LATAM: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)212
TABLE 308LATAM: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)213
TABLE 309LATAM: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)213
TABLE 310LATAM: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)213
TABLE 311LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)214
TABLE 312LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)214
TABLE 313LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)214
10.6MIDDLE EAST & AFRICA215
10.6.1MARKET GROWTH DRIVEN BY CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMA R&D215
TABLE 314MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)215
TABLE 315MEA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION)216
TABLE 316MEA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)216
TABLE 317MEA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)216
TABLE 318MEA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET,
BY TYPE, 2019–2026 (USD MILLION)217
TABLE 319MEA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)217
TABLE 320MEA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)217
TABLE 321MEA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)218
TABLE 322MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY INDICATION, 2019–2026 (USD MILLION)218
TABLE 323MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY APPLICATION, 2019–2026 (USD MILLION)218
TABLE 324MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET,
BY END USER, 2019–2026 (USD MILLION)219
 
11COMPETITIVE LANDSCAPE220
11.1OVERVIEW220
11.2KEY PLAYER STRATEGIES/RIGHT TO WIN221
FIGURE 28KEY PLAYER STRATEGIES IN THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, 2018–2021221
11.3MARKET SHARE ANALYSIS222
FIGURE 29CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020222
11.4REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS223
FIGURE 30REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS223
11.5COMPANY EVALUATION QUADRANT224
11.5.1STARS224
11.5.2EMERGING LEADERS224
11.5.3PERVASIVE PLAYERS224
11.5.4EMERGING COMPANIES224
FIGURE 31CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT, 2020225
11.6COMPANY EVALUATION QUADRANT: START-UPS/SMES226
11.6.1PROGRESSIVE COMPANIES226
11.6.2STARTING BLOCKS226
11.6.3RESPONSIVE COMPANIES226
11.6.4DYNAMIC COMPANIES226
FIGURE 32CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020227
11.7SERVICE FOOTPRINT OF COMPANIES228
TABLE 325SERVICE PORTFOLIO ANALYSIS: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET (2020)228
11.8REGIONAL FOOTPRINT OF COMPANIES229
TABLE 326REGIONAL FOOTPRINT OF COMPANIES: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET (2020)229
11.9COMPETITIVE SCENARIO230
TABLE 327CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
DEALS, JANUARY 2018–JUNE 2021230
TABLE 328CELL & GENE THERAPY MANUFACTURING SERVICES MARKET:
OTHER DEVELOPMENTS, JANUARY 2018 –JUNE 2021231
12COMPANY PROFILES232
12.1KEY MARKET PLAYERS232
(Business Overview, Services Offered, Recent Developments, and MnM View)*
12.1.1THERMO FISHER SCIENTIFIC, INC.232
TABLE 329THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW232
FIGURE 33THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)233
12.1.2MERCK KGAA237
TABLE 330MERCK KGAA: BUSINESS OVERVIEW237
FIGURE 34MERCK KGAA: COMPANY SNAPSHOT (2020)238
12.1.3CHARLES RIVER LABORATORIES241
TABLE 331CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW241
FIGURE 35CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020)242
12.1.4LONZA245
TABLE 332LONZA: BUSINESS OVERVIEW245
FIGURE 36LONZA: COMPANY SNAPSHOT (2020)246
12.1.5CATALENT, INC.251
TABLE 333CATALENT, INC.: BUSINESS OVERVIEW251
FIGURE 37CATALENT, INC.: COMPANY SNAPSHOT (2020)252
12.1.6TAKARA BIO INC.257
TABLE 334TAKARA BIO INC.: BUSINESS OVERVIEW257
FIGURE 38TAKARA BIO INC.: COMPANY SNAPSHOT (2020)258
12.1.7OXFORD BIOMEDICA PLC260
TABLE 335OXFORD BIOMEDICA PLC: BUSINESS OVERVIEW260
FIGURE 39OXFORD BIOMEDICA PLC: COMPANY SNAPSHOT (2020)260
12.1.8CELL AND GENE THERAPY CATAPULT263
TABLE 336CELL AND GENE THERAPY CATAPULT: BUSINESS OVERVIEW263
FIGURE 40CELL AND GENE THERAPY CATAPULT: COMPANY SNAPSHOT (2020)264
12.1.9F. HOFFMANN-LA ROCHE LTD.267
TABLE 337F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW267
FIGURE 41F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)267
12.1.10FUJIFILM HOLDINGS CORPORATION269
TABLE 338FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW269
FIGURE 42FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)270
12.1.11WUXI APPTEC272
TABLE 339WUXI APPTEC: BUSINESS OVERVIEW272
FIGURE 43WUXI APPTEC: COMPANY SNAPSHOT (2020)273
12.1.12NIKON CORPORATION275
TABLE 340NIKON CORPORATION: BUSINESS OVERVIEW275
FIGURE 44NIKON CORPORATION: COMPANY SNAPSHOT (2020)276
12.2OTHER PLAYERS277
12.2.1THE DISCOVERY LABS LLC277
TABLE 341THE DISCOVERY LABS LLC: BUSINESS OVERVIEW277
12.2.2ROSLINCT278
TABLE 342ROSLINCT: BUSINESS OVERVIEW278
12.2.3JRS PHARMA279
TABLE 343JRS PHARMA: BUSINESS OVERVIEW279
12.2.4FINVECTOR280
TABLE 344FINVECTOR: BUSINESS OVERVIEW280
12.2.5ABL, INC.281
TABLE 345ABL, INC.: BUSINESS OVERVIEW281
12.2.6RESILIENCE, INC.283
TABLE 346RESILIENCE, INC.: BUSINESS OVERVIEW283
12.2.7BIOCENTRIQ284
TABLE 347BIOCENTRIQ: BUSINESS OVERVIEW284
12.2.8PORTON BIOPHARMA LIMITED285
TABLE 348PORTON BIOPHARMA LIMITED: BUSINESS OVERVIEW285
12.2.9ANDELYN BIOSCIENCES286
12.2.10COMMERCIALIZING LIVING THERAPIES286
12.2.11VIBALOGICS287
12.2.12ANEMOCYTE SRL287
12.2.13ELEVATE BIO288
* Business Overview, Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13APPENDIX289
13.1DISCUSSION GUIDE289
13.2KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL296
13.3AVAILABLE CUSTOMIZATIONS298
13.4RELATED REPORTS298
13.5AUTHOR DETAILS299

お問合せフォーム